World Congress Insulin Resistance
DIABETES & CARDIOVASCULAR DISEASE

December 4−7, 2019
Hilton Universal City Hotel
Los Angeles, CA

www.WCIR.org
Welcome.

It is my pleasure to invite you to the 17th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), where we pursue our theme: Exploring New Frontiers in Metabolism—Tomorrow’s Clinical Science Today. Since its inception, this congress has become the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), metabolism and energy balance. It provides an exclusive opportunity for practicing professionals, clinical and basic scientists, researchers and other clinicians to collaborate on emerging scientific principles and management strategies. The WCIRDC faculty consists of distinguished global experts who link research to clinical practice in a bench-to-bedside approach that is unique to this state-of-the-art program.

This year, we honor Dr. Zachary Bloomgarden’s contributions to the understanding through education of insulin resistance, diabetes, and cardiometabolic conditions by presenting him with the “Gerald Reaven Distinguished Leader in Insulin Resistance Award.” Dr. Bloomgarden is a Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York and Editor-in-Chief of the Journal of Diabetes. His keynote lecture will be “Insulin Resistance, Type 2 Diabetes, Cardiovascular Disease: Looking Back, Looking Forward.” In addition, we will also acknowledge the incredible work, leadership, and contributions of Dr. Robert Henry by awarding him with the “Distinguished Leader in Insulin Resistance Award.” Dr. Henry is a Professor of Medicine at UCSF and Chief of Endocrinology, Metabolism & Diabetes of the Veterans Affairs Healthcare System in San Diego, California.

New this year, we added a half-day starting with a session on Insulin Resistance, Obesity and Co-Morbidities followed by a joint symposium of the Journal of Metabolism and WCIRDC on the impact of insulin resistance on metabolism. In addition, this year we will showcase a Salk Institute Symposium on “Insulin Resistance: Origin and Treatment” and a symposium featuring The TIMI Study Group covering TIMI’s CVOTs in diabetes, hyperlipidemia, obesity, and atrial fibrillation. Further highlights this year include a special session chaired by Dr. Ralph DeFronzo entitled “Has Our View About the Etiology of Diabetic Nephropathy Become Too Myopic?” and a special debate - leading the way beyond guidelines - on how to choose the best medications for patients with established cardiovascular disease. Additional topics covered in this year’s program include lipid disorders and management, atherosclerosis, medical diets, hypoglycemia and the brain, CHF, NAFLD/NASH, SGLT1 & SGLT2 inhibitors, bariatric surgery, sarcopenia & aging, managing high-risk older patients and youth with T2DM, addressing the contemporary role of older medications like sulfonylureas, insulin, HRT impact on diabetes, a what’s in the pipeline symposium and much more!

At the 17th WCIRDC, attendees will be able to participate in clinical workshops, meet the expert sessions and clinical lectures, all of which provide an opportunity to personally interact with the world’s top professionals in an intimate setting. Every session will conclude with another unique feature of the Congress: expert commentary on the clinical implications of basic and scientific research and Q&A and Panel Discussions.

I look forward to having you join us for this exciting program in Universal City, Los Angeles from December 4–7, 2019!

Best regards,

Yehuda Handelsman, MD
Chair & Program Director

---

Scientific Organizing Committee - International Committee for Insulin Resistance - ICIR

Yehuda Handelsman, MD Chair
Tarzana, CA

Zachary T. Bloomgarden, MD
New York, NY

Sonia Caprio, MD
New Haven, CT

Robert J. Chilton, DO
San Antonio, TX

Jaime A. Davidson, MD
Dallas, TX

Ralph A. DeFronzo, MD
San Antonio, TX

Daniel Einhorn, MD
La Jolla, CA

Vivian A. Fonseca, MD
New Orleans, LA

W. Timothy Garvey, MD
Birmingham, AL

Peter J. Grant, MD
Leeds, United Kingdom

George Grunberger, MD
Bloomfield Hills, MI

Paul S. Jellinger, MD
Hollywood, FL

Samuel Klein, MD
St. Louis, MO

Mikhail N. Kosiborod, MD
Kansas City, MO

Ronald M. Krauss, MD
Berkeley, CA

Derek LeRoith, MD, PhD
New York, NY

Philip Levy, MD
Phoenix, AZ

Christos Montzoros, MD, PhD
Boston, MA

Nikolaus Marx, MD
Aachen, Germany

Tracey L. McLaughlin, MD
Stanford, CA

Christian W. Mende, MD
La Jolla, CA

Jorge Plutzky, MD
Boston, MA

Richard Pratley
Orlando, FL

Arun J. Sanyal, MD
Richmond, VA

Alan R. Sinaiko, MD
Minneapolis, MN

Bart Staels, PhD
Lille, France

Paul Zimmet, AO, MD, PhD
Melbourne, Australia
PROGRAM DESCRIPTION

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 17th year, is a unique and exciting multidisciplinary CME program. The Congress is the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

For nearly two decades, WCIRDC has brought researchers, physicians, clinicians, and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside. “I heard it first at the Congress” is a frequent remark from the audience over the years, many of whom attend year after year. Researchers present their latest data and findings on everything from biomarkers to new physiological insights to novel ideas for therapies. WCIRDC offers attendees a unique experience to interact in an intimate setting with the distinguished global faculty for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.

PROGRAM OBJECTIVES

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, and CVD, the Congress’ focus has expanded to cover fat cells, lipids, the kidney, fatty liver, the brain, bone and energy metabolism, inflammation, aging, diet, cancer and more. The Congress addresses dyslipidemia, atherosclerosis, hypertension, and hypercoagulation as well as new pharmaceutical interventions such as incretins, SGLT2’s, PCSK9’s and EPA omega 3, to name a few. The goal is to understand the state-of-the-art pathophysiology of each condition and develop appropriate comprehensive clinical management strategies.

For primary care clinicians, the Congress will feature a series of workshops and “meet the expert” panels addressing the clinical prevention and management of kidney disease, diabetes, obesity, lipids, the high-risk CVD, CHF patient and more. To make basic and clinical research topics relevant to clinical medicine, following the presentations, there will be commentaries on clinical implications to practice by recognized global experts. The Congress’ intimate setting promotes personal contact between participants and the distinguished global faculty wherein everyone learns from the free flow of questions, personal observations and face to face informal discussions.

The Congress attracts state-of-the-art abstracts by young, upcoming and recognized leaders from around the globe. These abstracts will be published in Metabolism: Clinical and Experimental, a peer-reviewed journal published twelve times a year with over 40,000 unique monthly viewers worldwide that are in the top 10% of endocrinology, diabetes, and metabolism journals www.metabolismjournal.com.

Further, articles about the meeting are published in several medical journals and online medical news sources such as Diabetes Care, Metabolism, The Journal of Diabetes, Endocrine Practice, Diabetes, and Vascular Disease Research, Endocrinology Today, Cardiology Today, Endocrine Web, Clinical Endocrinology News, Diabetes in Control, among others.

TARGET AUDIENCE

This educational initiative is designed for cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dietitians, nurse practitioners, pharmacists, and any other health care professionals who are interested in improving patients outcome, focusing on insulin resistance, diabetes, obesity, cardiovascular disease, related kidney and fatty liver morbidity, and potential prevention and management impact on health and society.
### SESSION #1  INSULIN RESISTANCE, OBESITY AND CO-MORBIDITIES
Chairs: Ronald M. Krauss, MD  •  Paul Zimmet, AO, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:10 pm</td>
<td>Insulin Resistance: All You Wanted to Know - Finally Get the Right Answer</td>
<td>Ralph A. DeFronzo, MD</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>Effect of Very Low Carb vs Very Low Fat Diet on Adipose Tissue and FFA Metabolism</td>
<td>Tracey L. McLaughlin, MD</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>The Prevention of T2 Diabetes</td>
<td>W. Timothy Garvey, MD</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>Aging Co-Morbidities - How We Can Stem Multiple Hallmarks of Aging to Treat Cardiometabolic Diseases: Dolphin Models</td>
<td>Stephanie Venn-Watson, DVM, MPH</td>
</tr>
<tr>
<td>4:40 pm</td>
<td>Obesity &amp; Diabetes Related Cancers: Similarities and Differences</td>
<td>Derek LeRoith, MD, PhD</td>
</tr>
</tbody>
</table>

#### Q&A Panel Discussion

#### Refreshment Break

### SESSION #2  JOURNAL OF METABOLISM & WCIRDC: JOINT SESSION ON INSULIN RESISTANCE & METABOLISM
Chair: Christos S. Mantzoros, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:45 pm</td>
<td>EIC Intro, Journal Progress, Topics</td>
<td>Christos S. Mantzoros, MD, PhD</td>
</tr>
<tr>
<td>5:50 pm</td>
<td>Mediterranean Diet Impact on Diabetes and Cardiometabolic Conditions</td>
<td>George A. Bray, MD, PhD</td>
</tr>
<tr>
<td>6:10 pm</td>
<td>Exercise, Insulin Resistance, Diabetes and CVD</td>
<td>Nikolaos Perakakis, MD, PhD</td>
</tr>
<tr>
<td>6:30 pm</td>
<td>Hormonal Pathways and Molecular Mechanisms Underlying Cardiometabolic Disorders</td>
<td>Stella Daskalopoulou, MD</td>
</tr>
<tr>
<td>6:50 pm</td>
<td>Novel Therapies for Metabolic Disorders</td>
<td>Adrian Vella, MD, PhD</td>
</tr>
<tr>
<td>7:10 pm</td>
<td>Young Investigator Award, Brain and Metabolism: The Next Frontier</td>
<td>Olivia Farr, PhD</td>
</tr>
</tbody>
</table>

#### Post-CME Questions

### CME DINNER SYMPOSIUM
Supported by an Educational Grant from: Amarin

#### EPA–Icosapent Ethyl – Role in Clinical Practice
Chairs: Michael Miller, MD  •  Yehuda Handelsman, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 pm</td>
<td>Introduction &amp; Pre-CME Questions</td>
<td>Michael Miller, MD, MD</td>
</tr>
<tr>
<td>7:40 pm</td>
<td>EPA – Outcome REDUCE-IT – CV Related Pathophysiology and Clinical Implications Results, Pathophysiology of EPA – Clinical Implications</td>
<td>William S. Weintraub, MD, Yehuda Handelsman, MD</td>
</tr>
<tr>
<td>8:00 pm</td>
<td>Economic Impact of EPA – Icosapent Ethyl – on Practice</td>
<td>James A. Underberg, MD</td>
</tr>
<tr>
<td>8:15 pm</td>
<td>Contemporary Management Guidelines for ASCVD Prevention</td>
<td>Aruna Pradhan, MD, Sergio Fazio, MD</td>
</tr>
<tr>
<td>8:30 pm</td>
<td>Patient Cases</td>
<td></td>
</tr>
<tr>
<td>8:45 pm</td>
<td>A. Diabetes Primary Prevention</td>
<td></td>
</tr>
<tr>
<td>9:15 pm</td>
<td>B. Established CVD</td>
<td></td>
</tr>
<tr>
<td>9:30 pm</td>
<td>C. Diabetes Established CVD</td>
<td></td>
</tr>
</tbody>
</table>

#### Q&A Panel Discussion
Recognizing Features to Identify the Appropriate Patient for EPA – Icosapent Ethyl

**Panel:** Sergio Fazio, MD, PhD  •  Aruna Pradhan, MD  •  James A. Underberg, MD  •  William S. Weintraub, MD

**Moderator:** Michael Miller, MD  •  Yehuda Handelsman, MD

#### Post-CME Questions

#### Adjourn
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 am – 7:45 am</td>
<td>Breakfast Session Non-CME Actionable Insights to Optimize Time in Range with the FreeStyle Libre 14 Day System Supported by: Abbott</td>
</tr>
<tr>
<td>7:00 am – 8:00 am</td>
<td>Registration</td>
</tr>
<tr>
<td>7:45 am – 8:00 am</td>
<td>Welcome &amp; Introduction</td>
</tr>
<tr>
<td>8:00 am – 8:10 am</td>
<td>Pre-CME Questions</td>
</tr>
<tr>
<td>7:00 am – 8:00 am</td>
<td>Registration</td>
</tr>
<tr>
<td>8:00 am – 8:10 am</td>
<td>Welcome &amp; Introduction</td>
</tr>
<tr>
<td>8:10 am – 8:20 am</td>
<td>Pre-CME Questions</td>
</tr>
<tr>
<td>8:20 am</td>
<td>SESSION #3 TYPE 2 DIABETES IN YOUTH - MEDICATIONS</td>
</tr>
<tr>
<td></td>
<td>Chairs: Alan R. Sinaiko, MD • Philip Levy, MD</td>
</tr>
<tr>
<td>8:20 am</td>
<td>Comparisons from the RISE Medication Study: Are Youths with Early Onset Diabetes Responding Differently to Metformin and Insulin Treatment than Adults</td>
</tr>
<tr>
<td>8:40 am</td>
<td>The Challenge of Managing Youth-Onset T2DM with Currently Approved Medications: Time to Change Strategies</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>Q+A Panel Discussion</td>
</tr>
<tr>
<td>8:10 am – 8:20 am</td>
<td>Welcome &amp; Introduction</td>
</tr>
<tr>
<td>8:20 am</td>
<td>SESSION #4 EMERGING SCIENCE</td>
</tr>
<tr>
<td></td>
<td>Chairs: Derek LeRoith, MD, PhD • W. Timothy Garvey, MD</td>
</tr>
<tr>
<td>8:20 am</td>
<td>Clusterin Impairs Hepatic Insulin Sensitivity and Adipocyte Clusterin Associates with Cardiometabolic Risk</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>Q+A Panel Discussion</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>Refreshment Break at Exhibit Hall</td>
</tr>
<tr>
<td>8:20 am</td>
<td>SESSION #5 THE STATUS OF CHF</td>
</tr>
<tr>
<td></td>
<td>Chairs: Peter J. Grant, MD • Zachary T. Bloomgarden, MD</td>
</tr>
<tr>
<td>8:20 am</td>
<td>Heart Failure with Preserved Ejection Fraction in Diabetes: A Benign Marker of Accelerated Aging</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>Q+A Panel Discussion</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>Refreshment Break at Exhibit Hall</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>Session #6 INSULIN SECRETION &amp; CLEARANCE</td>
</tr>
<tr>
<td></td>
<td>Chairs: Tracey L. McLaughlin, MD • Bart Staels, PhD</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>What’s Clear About Clearance</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>The Balances of Insulin Secretion and Glucose Disposal in the Fed and Fasting States</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>Q+A Panel Discussion</td>
</tr>
<tr>
<td>9:00 am – 9:10 am</td>
<td>Lunch Session Non-CME Reviewing A1C and Cardiovascular Safety Data in T2D Therapies Supported by: Novo Nordisk</td>
</tr>
<tr>
<td>10:25 am – 10:55 am</td>
<td>Lunch Session Non-CME Reviewing A1C and Cardiovascular Safety Data in T2D Therapies Supported by: Novo Nordisk</td>
</tr>
<tr>
<td>12:40 pm – 1:40 pm</td>
<td>Lunch Session Non-CME Reviewing A1C and Cardiovascular Safety Data in T2D Therapies Supported by: Novo Nordisk</td>
</tr>
<tr>
<td>1:45 pm – 2:35 pm</td>
<td>MEET THE EXPERT</td>
</tr>
<tr>
<td></td>
<td>Cardiology, Lipids, Imaging</td>
</tr>
<tr>
<td></td>
<td>Is Glucose Management Really Important in DM?</td>
</tr>
<tr>
<td></td>
<td>Insulin Resistance &amp; Diabetes</td>
</tr>
<tr>
<td></td>
<td>Hormones and Metabolism</td>
</tr>
<tr>
<td>1:45 pm – 2:35 pm</td>
<td>Mandarin Room, Rich's Room, Hotel Room</td>
</tr>
<tr>
<td></td>
<td>Robert Chilton, DO</td>
</tr>
<tr>
<td>2:40 pm</td>
<td>SESSION #7 THE TIMI GROUP @ WCIRDC</td>
</tr>
<tr>
<td></td>
<td>Chairs: Robert P. Giugliano, MD • Erin Bohula May, MD, DPhil</td>
</tr>
<tr>
<td>2:40 pm</td>
<td>ENGAGE AF-TIMI 48: Patients with DM, AF on Oral Anticoagulants</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>CAMELIA-TIMI 61: Prevention of New Onset Diabetes &amp; Other Risk Factor Modifications with Lorcaserin</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>2019 Updates Dapagliflozin from DECLARE-TIMI 58</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>FOURIER and VESALIUS-CV: From Secondary Prevention of CV Events with</td>
</tr>
<tr>
<td></td>
<td>Evolocumab in Diabetics (FOURIER) on to Primary Prevention (VESALIUS-CV)</td>
</tr>
<tr>
<td>4:00 pm – 4:15 pm</td>
<td>Q+A Panel Discussion</td>
</tr>
<tr>
<td>4:15 pm – 4:45 pm</td>
<td>Refreshment Break at Exhibit Hall</td>
</tr>
</tbody>
</table>
**SESSION #8  MEDICAL DIETS**  
**Chairs:** Ronald M. Krauss, MD • Samuel Klein, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:45 pm</td>
<td>Ketogenic Diet for Diabetes</td>
<td>Sarah Hallberg, DO</td>
</tr>
<tr>
<td>5:05 pm</td>
<td>Overview of Intermittent Fasting</td>
<td>Samuel Klein, MD</td>
</tr>
<tr>
<td>5:25 pm</td>
<td>Ketones, Integrative Metabolism, and the Failing Heart</td>
<td>Peter Crawford, MD, PhD</td>
</tr>
<tr>
<td>5:45 pm</td>
<td>Circadian Rhythms, Time-Restricted Eating, and Cardiometabolic Health</td>
<td>Emily Manoogian, PhD</td>
</tr>
<tr>
<td>6:05 pm  – 6:30 pm</td>
<td>Q+A Panel Discussion &amp; Post-CME Questions</td>
<td></td>
</tr>
</tbody>
</table>

**6:30 PM – 7:30 PM WELCOME AND POSTERS RECEPTION**

**SEVEN #8  CME DINNER SYMPOSIUM**  
**DIABETES AND THE CARDIORENAL SYNDROME**  
**Chair:** Peter A. McCullough, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 pm</td>
<td>Introduction &amp; Pre-CME Questions</td>
<td>Janani Rangaswami, MD</td>
</tr>
<tr>
<td>7:40 pm</td>
<td>The Cardiorenal Syndrome in Diabetes, Epidemiology and Economic Impact</td>
<td>Peter A. McCullough, MD</td>
</tr>
<tr>
<td>8:00 pm</td>
<td>Classification, Pathophysiology and Diagnosis of The Cardiorenal Syndrome</td>
<td>Hector O. Ventura, MD</td>
</tr>
<tr>
<td>8:20 pm</td>
<td>Contemporary Approach to Management and Prognosis of the Cardiorenal Syndrome in Diabetes</td>
<td>Mark E. Molitch, MD</td>
</tr>
<tr>
<td>8:40 pm</td>
<td>Emerging Therapies: The SGLT2 Inhibitors in People with T2D at Risk for Cardiorenal Syndrome</td>
<td>Norman E. Lepor, MD</td>
</tr>
<tr>
<td>9:00 pm</td>
<td>Q&amp;A Panel Discussion: Practice Implication of CRS- Management and Prevention - Case based</td>
<td></td>
</tr>
<tr>
<td>9:30 pm</td>
<td>Adjourn - Dessert Reception To Follow</td>
<td></td>
</tr>
</tbody>
</table>

**FRIDAY, DECEMBER 6, 2019**

**SESSION #9  HAS OUR VIEW ABOUT THE ETIOLOGY OF DIABETIC NEPHROPATHY BECOME TOO MYOPIC?**  
**Chairs:** Ralph A. DeFronzo, MD • Christian W. Mende, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 am</td>
<td>Diabetic Nephropathy: The Ominous Octet and More</td>
<td>Ralph A. DeFronzo, MD</td>
</tr>
<tr>
<td>8:35 am</td>
<td>Hypoxia: The Real Culprit Responsible for Diabetic Kidney Disease</td>
<td>Per-Henrik Groop, MD</td>
</tr>
<tr>
<td>8:55 am</td>
<td>The Tubular Hypothesis of Diabetic Nephropathy</td>
<td>Volker Vallon, MD</td>
</tr>
<tr>
<td>9:35 am  – 9:55 am</td>
<td>Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION #10  ASCVD IN DM: PATHOPHYSIOLOGY, PREVENTION & MANAGEMENT**  
**Chairs:** Bart Staels, PhD • Nikolaus Marx, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:55 am</td>
<td>Atherosclerosis Burden in T1DM, T2DM and the General Population</td>
<td>Matthew J. Budesof, MD</td>
</tr>
<tr>
<td>10:15 am</td>
<td>ESC/EASD 2019 Guidelines: The Prevention and Management of Cardiovascular Disease in Diabetes</td>
<td>Peter J. Grant, MD</td>
</tr>
<tr>
<td>10:35 am</td>
<td>Q+A Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>10:50 am – 11:20 am</td>
<td>Refreshment Break at Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION #11  CONTEMPORARY APPROACH TO MANAGING DIABETES**  
**Chairs:** Daniel Einhorn, MD • Vivian A. Fonseca, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 am</td>
<td>Non-Insulin Medications in the Treatment of T1D- Focus on SGLT1 &amp; 2 Inhibitors</td>
<td>Satish K. Garg, MD</td>
</tr>
<tr>
<td>11:40 am</td>
<td>Do We Still Have to Inject to Manage Diabetes?</td>
<td>George Grunberger, MD</td>
</tr>
</tbody>
</table>
SESSION #12  |  SALK INSTITUTE SYMPOSIUM - INSULIN RESISTANCE: ORIGIN AND TREATMENT  
Chair: Ronald M. Evans, PhD  
2:15 pm  |  FGF1: Control of Adipose Remodeling and Insulin Sensitivity  
Ronald M. Evans, PhD  
2:35 pm  |  Inflammatory Links Between Obesity and Insulin Resistance  
Alan R. Saltiel, PhD  
2:55 pm  |  Rethinking the Role of the Brain in Glucose Homeostasis and Diabetes Pathogenesis  
Michael W. Schwartz, MD  
3:15 pm – 3:30 pm  |  Q+A Panel Discussion  

SESSION #13  |  A GLIMPSE TO THE FUTURE - WHAT'S IN THE PIPELINE?  
Non-CME  
Chairs: Ralph A. DeFronzo, MD  •  Christos S. Mantzoros, MD, PhD  
3:30 pm  |  AstraZeneca  
Danilo Verge, MD, MBA  
3:45 pm  |  Medtronics  
Ali Dianaty, MBA  
4:00 pm  |  Poxel  
Julie Dubourg, MD  
4:15 pm – 4:45 pm  |  Refreshment Break at Exhibit Hall  
4:45 pm  |  Janssen  
James F. List, MD, PhD  
5:00 pm  |  Sanofi  
Tony Muslin, MD  
5:15 pm – 5:30 pm  |  Q+A Panel Discussion  

SESSION #14  |  FATTY LIVER DISEASE & NASH  
Chairs: Paul Zimmet, AO, MD, PhD  •  Sonia Caprio, MD  
5:30 pm  |  NAFLD and Cardiometabolic Outcomes: Pathophysiology and Emerging Therapies  
Christos S. Mantzoros, MD, PhD  
5:50 pm  |  The Role of Immune-Inflammation in NASH  
Bart Staels, PhD  
6:10 pm  |  Therapeutic Advances for NASH  
Arun J. Sanyal, MD  
6:30 pm – 6:45 pm  |  Q+A Panel Discussion & Post-CME Questions  

6:45 PM – 8:15 PM  |  ABSTRACT ORAL PRESENTATIONS  
SALON 6AB  
Zachary T. Bloomgarden, MD, Chair  •  Daniel Einhorn, MD  •  George Grunberger, MD  •  Philip Levy, MD  
Abstracts are published in Metabolism  
Editor-in-Chief: Christos S. Mantzoros, MD, PhD  

7:00 pm – 8:00 pm  |  Dinner Session  
Non-CME  
Dinner Session  
Daniel Einhorn, MD  
CREDENCE Landmark Trial: Canagliflozin and RenalEndpoints in Diabetes with Supported by: Janssen  
Established Nephropathy Clinical Evaluation Clinical Trial  

SESSION #15  |  CIRCADIAN VS METABOLIC SYNDROME  
Chairs: Samuel Klein, MD  •  Kurt GMM Alberti, DPhil  
POINT-COUNTER-POINT: SHOULD THE METABOLIC SYNDROME BE CHANGED TO CIRCADIAN SYNDROME?  
8:00 am  |  Yes  
Paul Zimmet AO, MD, PhD  
8:20 am  |  No  
Robert H. Eckel, MD  
8:40 am – 8:55 am  |  Q+A Panel Discussion  

SATURDAY, DECEMBER 7, 2019

6:45 am – 7:45 am  |  Breakfast Session  
Non-CME  
Breakfast Session  
Matthew J. Budoff, MD  
Expert Insights: Managing Cardiovascular Risk Based on a Landmark CV Outcomes Study  
Supported by: Amarin  

7:45 am – 7:50 am  |  Abstract Oral Winners Presentations  
7:50 am – 7:55 am  |  Summary of Second Day  
7:55 am – 8:00 am  |  Pre-CME Questions  
Zachary T. Bloomgarden, MD
AWARD PRESENTATION  Presented by: Daniel Einhorn, MD & Vivian A. Fonseca, MD

8:55 am  DISTINGUISHED LEADER IN INSULIN RESISTANCE  Robert R. Henry, MD

SESSION #16  IMPACT OF CVOT IN 2019  Chairs: Robert J. Chilton, DO • Nikolaus Marx, MD

9:00 am  Management of the High-Risk Older Patient Based on the Contemporary CVOT  Richard E. Pratley, MD
9:20 am  CHF & CVOTs- DEFINE-HF, DAPA-HF and THEMIS  Mikhail N. Kosiborod, MD
9:40 am  Critical Appraisal of 2019 CVOT  Sanjay Kaul, MD
10:00 am — 10:15 am  Q+A Panel Discussion
10:15 am — 10:35 am  Refreshment Break

AWARD PRESENTATION  Presented by: Daniel Einhorn, MD & Paul Zimmet, AO, MD, PhD

10:35 am  GERALD REAVEN DISTINGUISHED LEADER IN INSULIN RESISTANCE  Zachary T. Bloomgarden, MD

KEY NOTE  Insulin Resistance, Type 2 Diabetes, Cardiovascular Disease: Looking Back, Looking Forward

SESSION #17  LIPIDS – TODAY AND TOMORROW  Chairs: Paul S. Jellinger, MD • Mikhail N. Kosiborod, MD

11:05 am  Contemporary & Future Management of LDL  Sergio Fazio, MD, PhD
11:25 am  Dyslipidemia Management - Beyond LDL - in the Prevention of ASCVD  Christie M. Ballantyne, MD
11:45 am – 12:00 pm  Q+A Panel Discussion

CONCURRENT SESSIONS  CLINICAL WORKSHOPS  Lunch will be provided

12:00 pm — 1:00 pm  
- Vaccinations in Diabetes  Hiro Room  Jaime A. Davidson, MD
- Lipids — Intensive Management  Club Room  Paul S. Jellinger, MD • Paul D. Rosenblit, MD, PhD
- How to Use CGM  Mandarin AB  Daniel Einhorn, MD
- Kidney Disease — 2019 Prevention & Management  Salon 6AB  Christian W. Mende, MD

SESSION #18  CONTEMPORARY ROLE OF OLDER MEDS IN THE MANAGEMENT OF DIABETES  Chairs: George Grunberger, MD • Richard E. Pratley, MD

1:00 pm  Cardiovascular Safety of Sulfonylureas – The Long Journey from UGDP to CAROLINA  Nikolaus Marx, MD
1:20 pm  Incorporating Generic Oral Anti-Hyperglycemic Medications in Treatment of DM  Vivian A. Fonseca, MD
1:40 pm  The Role of Insulin in the Management of T2D in the CVOT Era  Matthew C. Riddle, MD
2:00 pm  Hypoglycemia Impact on the Brain  Stephanie Amiel, MD
2:20 pm – 2:40 pm  Q+A Panel Discussion
2:40 pm – 3:00 pm  Refreshment Break

SESSION #19  CO-MORBIDITIES OF CHILDHOOD DIABETES  Chairs: Sonia Caprio, MD • Tracey L. McLaughlin, MD

3:00 pm  Youth with Type 2 Diabetes Develop Complications More Often Than Type 1 Peers  Dana Dabelea, MD, PhD
3:20 pm  Relation of Childhood Cardiovascular Risk Factors to Adult Cardiovascular Disease  Alan R. Sinaiko, MD
3:40 pm – 3:50 pm  Q+A Panel Discussion

SESSION #20  INTERPRETING CVOT – IMPLICATIONS FOR PRACTICE  Chairs: Vivian A. Fonseca, MD • Peter J. Grant, MD

DEBATE: THE APPROPRIATE MEDICATION PREVENTING THE NEXT EVENT IN A PATIENT WITH DM & ESTABLISHED CVD?

3:50 pm  Case Presentation  Yahuda Handelsman, MD
3:55 pm  SGLT2i  Sunder Mudaliar, MD
4:05 pm  PCSK9i  Sergio Fazio, MD, PhD
4:15 pm  GLP1-ra  Richard E. Pratley, MD
4:25 pm  EPA  Christie M. Ballantyne, MD
4:35 pm - 5:00 pm  Q+A Panel Discussion & Post-CME Questions
5:00 pm  Adjourn
FACULTY 2019

Yohuda Handelsman, MD, FACP, FNIA, FASPC, MACE
Chair & Program Director
17th WCDC & 4th HD
Medical Director & Principal Investigator
Metabolic Institute of America
Chair & Founder
International Committee for Insulin Resistance
Chair & Founder
International Lipid Forum
Tarzana, California

Kurt GMA Alberti, DPhil, FRCP, FRCPath
Senior Research Investigator
Section of Diabetes, Endocrinology and Metabolism
Imperial College, London
Emeritus Professor of Medicine
University of Newcastle, UK
Past-President IDF and EASD
London, United Kingdom

Stephanie Amiel, MBBS, MD
RD Lawrence Professor of Diabetic Medicine
Honorary Consultant Physician Diabetes Services
King’s College London
London, United Kingdom

Christie M. Ballantyne, MD, FACP, FACC
Chief, Sections of Cardiology and Cardiovascular Research
Professor and Vice Chair of Research, Department of Medicine
Director, Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, Texas

Richard N. Bergman, PhD
Alfred Joy Firestein Chair in Diabetes Research
Professor, Department of Biomedical Sciences, Cedars-Sinai
Director, Sports Spectacular Diabetes and Obesity Wellness and Research Center (SSDOWRC)
Professor-in-Residence, Department of Medicine, UCLA
Los Angeles, California

Zachary T. Bloomgarden, MD, MACE
Clinical Professor
Department of Medicine
Icahn School of Medicine at Mount Sinai
Editor, The Journal of Diabetes
New York, New York

Erin Babula May, MD, DPhil
Associate Physician in Cardiovascular Medicine Investigator, TIMI Study Group
Brigham & Women’s Hospital
Harvard Medical School
Boston, Massachusetts

George A. Bray, MD, MACP, MACE
Boyd Professor Emeritus
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, Louisiana

Matthew J. Budoff, MD, FACC, FAHA
Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology Program Director, Director of Cardiac CT Harbor-UCLA Medical Center,
Division of Cardiology
Los Angeles, California

Sonia Caprio, MD
Professor of Pediatric Endocrinology
Yale University School of Medicine
New Haven, Connecticut

Robert J. Chilton, DO, FACC, FAHA
Professor of Medicine
Department of Medicine
Division of Cardiology
The University of Texas Health Science Center
San Antonio, Texas

Peter Crawford, MD, PhD
Professor, Departments of Medicine, and Biochemistry, Molecular Biology, and Biophysics
Vice Chair for Research, Dept. of Medicine
Director, Division of Molecular Medicine
University of Minnesota
Minneapolis, Minnesota

Dana Dabelea, MD, PhD
Conrad M. Riley Professor of Medicine
Director, Division of Molecular Medicine
Vice Chair for Research, Dept. of Medicine
University of Minnesota
Minneapolis, Minnesota

David A. D’Alessio, MD
Professor of Medicine
Chief, Division of Endocrinology, Metabolism & Nutrition
Associate Director, Duke Molecular Physiology Institute
Durham, North Carolina

Stella S. Daskalopoulou MD, MSc, DIC, PhD
Associate Professor (tenured) in Medicine FRQ-S
Chequeur-Bourrieur Clinician
Senior Director, Vascular Health Unit Department of Medicine, Division of Internal Medicine
McGill University, McGill University Health Centre
Montreal, QC Canada

Jaime A. Davidson, MD, FACP, MACE
Clinical Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism
Touchstone Diabetes Research Center
The University of Texas Southwestern Medical Center
Dallas, Texas

Ralph A. DeFronzo, MD
Professor of Medicine
Chief, Diabetes Division
University of Texas Health Science Center at San Antonio (UTHSCSA)
Deputy Director, Texas Diabetes Institute
San Antonio, Texas

Ali Dianaty, MBA
Non-CME Speaker
Vice President, R&D Diabetes Group
Medtronic Diabetes
Los Angeles, California

Julie Dubourg, MD
Non-CME Speaker
Medical Director, Clinical Development
Poxel Pharmaceuticals
Lyon, France

Robert H. Eckel, MD
Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
Professor of Physiology and Biophysics, Emeritus
Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado Anschutz Medical Campus
Denver, Colorado

Daniel Einhorn, MD, FACP, FACE
Chief, Diabetes and Endocrine Associates
Medical Director
Scripps Whittier Diabetes Institute
Clinical Professor
UCSD School of Medicine
La Jolla, California

Ali Dianaty, MBA
Non-CME Speaker
Vice President, R&D Diabetes Group
Medtronic Diabetes
Los Angeles, California

Julie Dubourg, MD
Non-CME Speaker
Medical Director, Clinical Development
Poxel Pharmaceuticals
Lyon, France

Robert H. Eckel, MD
Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
Professor of Physiology and Biophysics, Emeritus
Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado Anschutz Medical Campus
Denver, Colorado

Daniel Einhorn, MD, FACP, FACE
Chief, Diabetes and Endocrine Associates
Medical Director
Scripps Whittier Diabetes Institute
Clinical Professor
UCSD School of Medicine
La Jolla, California
FACULTY 2019

Ronald M. Evans, PhD
Professor and Director
Gene Expression Laboratory
Investigator, Howard Hughes Medical Institute
Salk Institute for Biological Studies
La Jolla, California

Sergio Fazio, MD, PhD
The William and Sonja Connor
Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Vivian A. Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tulsa Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulsa University Health Sciences Center
New Orleans, Louisiana

Satish K. Garg, MD
Professor of Medicine and Pediatrics
Garg Endowed Chairs & Director Adult Program
Barbara Davis Center for Diabetes
University of Colorado Denver
Editor-in-Chief, Diabetes Tech. & Therap.
Denver, Colorado

W. Timothy Garvey, MD
Butterworth Professor
Department of Nutrition Sciences
University of Alabama at Birmingham
GRECC Investigator
Birmingham VA Medical Center
Director, UAB Diabetes Research Center
Birmingham, Alabama

Robert P. Giugliano, MD, SM
Senior Investigator, BWH/TIMI Study Group
Physician, Cardiovascular Medicine
B Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Peter J. Grant, MD, FRCP, FMedSci
Professor of Medicine
Honorary Consultant Physician
University of Leeds
Leeds Teaching Hospitals NHS Trust
Division of Cardiovascular & Diabetes Research
LIGHT Laboratories
Leeds, United Kingdom

Per-Henrik Groop, MD, DMSc, FRCPE
Professor and Chair of Internal Medicine
Chief Physician
Abdominal Center Nephrology
University of Helsinki & Helsinki University Hospital
Helsinki, Finland

George Grunberger, MD, FACP, FACE
Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics
Wayne State University School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont School of Medicine
Visiting Professor, Internal Medicine
First Faculty of Medicine, Charles University Prague, Czech Republic
Past President, AACE
Bloomfield Hills, Michigan

Sarah Hallberg DO, MS, ACSM-CEP, FOMA, FNL
Medical Director
Medically Supervised Weight Loss
Indiana University Health Arnett
Indiana University School of Medicine
Medical Director, Virta Health
Aspen Institute Health Innovator Fellow
West Lafayette, Indiana

Villa Hsueh, MD
Director, Diabetes and Metabolism Research Center
Professor, Department of Internal Medicine
Division of Endocrinology, Diabetes and Metabolism
Ohio State University Wexner Medical Center
Columbus, Ohio

Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
Voluntary Faculty
University of Miami, Miller School of Medicine
The Center for Diabetes & Endocrine Care
Past President, AACE & ACE
Hollywood, Florida

Steven E. Kahn, MB, ChB
Professor of Medicine
Leonard L. Wright and Marjorie C. Wright Chair
VA Puget Sound Health Care System
University of Washington
Seattle, Washington

Sanjay Kaul, MD, FACC, FAHA
Professor of Medicine,
Division of Cardiology
Cedars-Sinai Medical Center
David Geffen School of Medicine at UCLA
Ronald Reagan UCLA Medical Center
Fellow, American Heart Association
Fellow, American College of Cardiology
Los Angeles, California

Mark Kearney, MBChB, MRCP, MD
British Heart Foundation Professor
Cardiovascular & Diabetes Research
Leeds Institute of Cardiovascular & Metabolic Medicine
Research Lead, Heart Failure Services
Dean, School of Medicine
University of Leeds
Leeds, United Kingdom

Samuel Klein, MD
William H. Danforth Professor of Medicine and Nutritional Science
Director, Center for Human Nutrition
Chief, Division of Geriatrics & Nutritional Science
Washington University School of Medicine
St. Louis, Missouri

Mikhail N. Kosiborod MD, FACC,
St. Louis, Missouri
Washington University School of Medicine
Chief, Division of Geriatrics & Nutritional Science
Director, Center for Human Nutrition
and Nutritional Science
William H. Danforth Professor of Medicine
Samuel Klein, MD
Leeds, United Kingdom

Ronald M. Krauss, MD
Senior Scientist and Director
Atherosclerosis Research
Children's Hospital Oakland Research Institute
Adjunct Professor
Department of Medicine, UCSF
Adjunct Professor
Department of Nutritional Sciences
University of California, Berkeley
Berkeley, California
FACULTY 2019
FACULTY 2019

Matthew C. Riddle, MD
Professor of Medicine
Division of Endocrinology, Diabetes, &
Clinical Nutrition
Oregon Health & Science University
Portland, Oregon

Paul D. Rosenbliit MD, PhD,
FACE, FNLA
Clinical Professor, Medicine
Division of Endocrinology, Diabetes, Metabolism
University of California, Irvine (UCI)
School of Medicine
Co-Director, Diabetes Outpatient Clinic
UCI Medical Center, Orange, CA
Director, & Site Principal Investigator,
Diabetes/Lipid Management & Research Center
Huntington Beach, California

Alan R. Saltiel, PhD
Professor of Medicine and Pharmacology
Director, Institute of Diabetes and
Metabolic Health
University of California, San Diego
Center Director, UCSD-UCLA Diabetes Research Center
La Jolla, California

Arun J. Sanyal, MBBS, MD
Professor of Medicine, Physiology and
Molecular Pathology
Division of Gastroenterology,
Hepatology and Nutrition
VCU Medical Center
Director, Education Core, CCTR
Virginia Commonwealth University
Richmond, Virginia

Michael W. Schwartz, MD
Robert H. Williams Endowed Chair
Co-Director UW Medicine Diabetes Institute
University of Washington
Seattle, Washington

Gerald I. Shulman, MD, PhD,
FACP, MACE
George R. Cowgill Professor of
Physiological Chemistry
Professor of Medicine and Cellular &
Molecular Physiology
Co-Director Yale Diabetes Research Center
Yale School of Medicine
New Haven, Connecticut, USA

Alan R. Sinaiko, MD
Professor, Department of Pediatrics
Division of Pediatric Nephrology
University of Minnesota Medical School
Minneapolis, Minnesota

Bart Steels, PhD
Full Professor, University of Lille
Director of Inserm UMR1011
European Genomics Institute for Diabetes &
Institute Pasteur de Lille
Lille, France

James A. Underberg, MD, MS,
FACPM, FACP, FNAM, FASPC, FALA
Clinical Assistant Professor of Medicine
Lipidology & Cardiovascular Disease Prevention
NYU Medical School & NYU Center for CV Prevention Director,
Bellevue Hospital Lipid Clinic Past-President
National Lipid Association
New York, New York

Volkner Vallon, MD
University of California San Diego
Department of Medicine and
Department of Pharmacology
Division of Nephrology & Hypertension &
VA San Diego Health Care System
San Diego, California

Adrian Vella, MD, FRCP (Edin.)
Professor of Medicine
Chair for Research
Department of Internal Medicine
Division of Endocrinology, Diabetes, Metabolism and Nutrition
Mayo Clinic
Rochester, Minnesota

Stephanie Venn-Watson,
DVM, MPH
Co-Founder, Chief Executive Officer
Epitracker, Inc.
Co-Founder, Chief Executive Officer
Seraphina Therapeutics
San Diego, California

Hector O. Ventura, MD, FACC, FACP
Professor of Medicine
Tulane University School Of Medicine Adult
Congenital Heart Disease, Heart Failure &
Transplantation Section Head Heart Failure And
Heart Transplantation Ochsner Clinic President
Louisiana Chapter Of The American College Of Cardiology
New Orleans, Louisiana

Danilo Verge, MD, MBA
Non-CME Speaker
Vice President
Cardiovascular, Renal and Metabolism
Global Medical Affairs
Therapeutic Areas
AstraZeneca
Gothenburg, Sweden

Elena Volpi, MD, PhD, FGSA
Director, Seely Center on Aging
Director, UTMB Claude D. Pepper Older Americans Independence Center
Associate Director
Institute for Translational Sciences
Professor, Departments of Internal Medicine-
Geriatrics, Neuroscience and Cell Biology
Nutrition and Metabolism
Associate Chair-for Research
Department of Internal Medicine
Graduate School of Biomedical Sciences at the
University of Texas Medical Branch
Galveston, Texas

William S. Weintraub, MD, MACC,
FAHA, FESC
Director of Outcomes Research
MedStar Washington Hospital Center
Washington, District of Columbia

Matthew R. Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Stephen D. Wiviott, MD
Executive Director, Clinical Trials Office
Partners HealthCare
Senior Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul Zimmet AQ, MD, PhD, FRACP,
FACP, FTSE
Doctor of Laws (Monash)
Doctor of Philosophy
Honorary Causa (Tel Aviv University)
Co-Director, Sagol Center for
Epigenetics of Aging and Metabolism
Tel Aviv Medical Center
Professor of Diabetes Research
Monash University
Honorary President
International Diabetes Federation
Melbourne, Australia
ACCREDITATION INFORMATION. You can earn up to 32 credits. This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement The PESI Inc. designated this live activity for a maximum of 32 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

International CME International Physicians are formally eligible for AMA PRA Category 1 Credit™.

Physician Assistants AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

Nurses For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CA Nurses Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 17th WCIRDC for approximately 32 contact hours.

Pharmacists For the purpose of recertification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. This course qualifies for XX continuing education hours.

Registered Dieticians For the purpose of recertification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.

Satisfactory Completion for credits All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.

PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Zachary T. Bloomgarden, MD • Sonia Caprio, MD • Robert J. Chilton, DO • Jaime A. Davidson, MD
Ralph A. DeFranzo, MD • Daniel Einhorn, MD • Vivian A. Fonseca, MD • W. Timothy Garvey, MD • George Grunberger, MD
Paul S. Jellinger, MD • Samuel Klein, MD • Mikhail N. Kosiborod, MD • Ronald M. Krauss, MD • Derek LeRoith, MD, PhD • Philip Levy, MD
• Christos S. Mantzoros, MD, DSc, PhD • Nikolaus Marx, MD • Tracey L. McLoughlin, MD • Christian W. Mende, MD • Jorge Plutzky, MD
Richard E. Pratley, MD • Arun J. Sanyal, MD • Alan R. Sinaiko, MD • Bart Staels, PhD • Paul Zimmet, AO, MD, PhD • Renee Asp, BS

The International Committee for Insulin Resistance Gratefully Acknowledges the Education Support of

PREMIER EDUCATOR
AstraZeneca

Pfizer-Merck Alliance

Lilly USA

EDUCATOR
Novo Nordisk
ACCOMMODATIONS

The 17th Annual World Congress on Insulin Resistance, Diabetes & CVD (WCIRDC) will be held at the prestigious Hilton Universal City Hotel.

The majestic Hilton Hotel is situated on a high hill above the Los Angeles entertainment district, near Universal Studios Hollywood and City Walk. The hotel is located a block from the main entrance of Universal Studios Hollywood and is also a 3.5-mile drive to Pantages Theatre for Broadway shows. This 24-story hotel offers upscale rooms with panoramic views of the Hollywood Hills and Universal Studios.

**Hilton Universal City Hotel**  
555 Universal Hollywood Drive Universal City, CA 91608

To reserve a room at our special rate of $214 a night for conference participants and their guests, call 818.506.2500 or visit [www.wcir.org/accommodations](http://www.wcir.org/accommodations).

Please reference the group name: **WCIRDC**

Rooms will be available on a first-come basis, and will be available until all are filled. Group room rates will be available three (3) days prior to and three (3) days after the event dates. If you need special accommodations or if you have any questions about access to any of our activities, please contact the meeting organizers at 818 342 1889 or [info@tmioa.com](mailto:info@tmioa.com).

---

**Corporate Opportunities & Exhibit Space Still Available**

Don’t miss the opportunity to be part of the 17th WCIRDC  
Showcase your products, services, and technologies!  
Reach out to the most influential leaders and decision-makers in the field  
Meet with globally-recognized medical leaders, clinicians and scientists, who will present and share their knowledge.

WCIRDC will dedicate an area, separate from the education program, where your company will be able to exhibit products, equipment, and services.

[info@tmioa.com](mailto:info@tmioa.com) | 818.342.1889 | [www.wcir.org](http://www.wcir.org)

---

**Save the Date • 18th WCIRDC • December 2-5, 2020**
Register online www.wcir.org/registration
Email us info@tmioa.com By phone 818 342-1889

Registration Fee Includes: CME credit, course materials, workshops, breakfast, lunch, refreshment breaks, CME Dinners, and welcome reception.

Cancellation Policy: A $75 cancellation fee will be charged for cancellation between September 2, 2019 and November 1, 2019. After November 1, 2019 there will be NO REFUND. Cancellations must be submitted via e-mail to info@tmioa.com or by phone at 818-342-1889.

You can earn up to 32.00 CME ACCME Credit

All Members of Participating Organizations Qualify for a Discount on Registration
Please email info@tmioa.com or call 818 342 1889 to receive a coupon code

PARTICIPATING ORGANIZATIONS
- American Academy of Physician Assistants (AAPA)
- American Association of Clinical Endocrinologists (AACE)
- American College of Cardiology (ACC)
- American Association for the Study of Liver Diseases (AASLD)
- American Board of Obesity Medicine (ABOM)
- American College of Nutrition (ACN)
- American Diabetes Association (ADA)
- American Gastroenterological Association (AGA)
- American Society of Endocrine Physician Assistants (ASEPA)
- American Society of Hypertension (ASH)
- American Society for Nutrition (ASN)
- American Society for Preventive Cardiology (ASPC)
- American Society for Preventive Oncology (ASPO)
- Androgen Excess & PCOS Society (AE-PCOS)
- European Society of Cardiology (ESC)
- Familial Hypercholesterolemia (FH) Foundation
- International Academy of Cardiology (IAC)
- Israel Endocrine Society (IES)
- Joslin Diabetes Center
- New Cardiovascular Horizons (NCVH)
- Pacific Lipid Association (PLA)
- Pediatric Endocrine Society (PES)
- Society for Endocrinology
- Society for Vascular Surgery (SVS)

MEDIA PARTNERS

Endocrinology Advisor Journal of Diabetes Physician's Weekly
Cardiology Today
Endocrine Today

The International Committee for Insulin Resistance Gratefully Acknowledges the Corporate Support of

SAPPHIRE LEVEL
- AMGEN

EMERALD LEVEL
- Lilly
- AMARIN
- Abbott
- novo nordisk®
- Janssen